Guy Jérusalem

22.6k citations
342 papers · 9.7k · 4 hit papers · h-index 50

Impact in

  • Oncology top 0.5%
    • HER2/EGFR in Cancer Research
    • Cancer Immunotherapy and Biomarkers
    • Cancer Treatment and Pharmacology
    • Breast Cancer Treatment Studies

Papers in

Guy Jérusalem

327 papers receiving 9.5k citations

Guy Jérusalem's Hit Papers

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival 2021 · 174 citations
1740+5+10Years since publication100200300400500

Peers

Guy Jérusalem
Comparison fields: 5 of 141
  • Oncology 3.9k
  • Cancer Research 1.5k
  • Pulmonary and Respiratory Medicine 2.9k
  • Pathology and Forensic Medicine 1.3k
  • Radiology, Nuclear Medicine and Imaging 1.5k
Replace Tanios Bekaii‐Saab with:
Tanios Bekaii‐Saab United States
Patrice Viens France
Vittorina Zagonel Italy
S. Monfardini Italy
Laura F. Hutchins United States
Mark Rosenthal Australia
Richard T. Penson United States
Ian S. Fentiman United Kingdom
Primo N. Lara United States
Gerold Bepler United States
Guy Jérusalem relative to Tanios Bekaii‐Saab United States Tanios Bekaii‐Saab's profile →
Citations per field
00.5×4.1×
Tanios Bekaii‐Saab · 1×
Citations per year

Countries citing papers authored by Guy Jérusalem

Since Specialization
Citations

This map shows the geographic impact of Guy Jérusalem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guy Jérusalem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guy Jérusalem more than expected).

Fields of papers citing papers by Guy Jérusalem

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guy Jérusalem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guy Jérusalem. The network helps show where Guy Jérusalem may publish in the future.

Co-authors

The 25 scholars most cited alongside Guy Jérusalem, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Guy Jérusalem Line = papers co-authored together Guy Jérusalem links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 342 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Hit paper breakdown →
2017597
2
Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer
Hit paper breakdown →
2010479
3 1999465
4
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Hit paper breakdown →
2020351
5 2016297
6
Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis.
2002260
7 2013249
8 2001225
9 2002176
10 2018175
11
Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.
2001175
12
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
Hit paper breakdown →
2021174
13 2015146
14 2021142
15 2016140
16 1999133
17 2019125
18 2010114
19 2014113
20 2011112

About Guy Jérusalem

Guy Jérusalem is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Radiology, Nuclear Medicine and Imaging and Molecular Biology, having authored 342 papers that have together received 9.7k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (98 papers), Cancer Treatment and Pharmacology (79 papers), HER2/EGFR in Cancer Research (60 papers), Breast Cancer Treatment Studies (30 papers), Medical Imaging Techniques and Applications (27 papers), PI3K/AKT/mTOR signaling in cancer (22 papers), Lymphoma Diagnosis and Treatment (22 papers) and Cancer Immunotherapy and Biomarkers (21 papers). The work is most often cited by research in Oncology (3.9k citations), Cancer Research (1.5k citations), Pulmonary and Respiratory Medicine (2.9k citations), Pathology and Forensic Medicine (1.3k citations) and Radiology, Nuclear Medicine and Imaging (1.5k citations). Guy Jérusalem has collaborated with scholars based in Belgium, United States and France. Frequent co-authors include Georges Fillet, Yves Béguin, Marie‐France Fassotte, P. Rigo, Fadi Najjar, Patrick Paulus, Joëlle Collignon, Laurence Lousberg, Hélène Schroeder and R. Hustinx. Their work appears in journals such as Annals of Oncology, Cancer Research, Journal of Clinical Oncology, Breast Cancer Research and Treatment and BMC Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact